UNICEF signs COVID-19 vaccine supply agreement with Moderna
COPENHAGEN/NEW YORK, 2 June 2021 – UNICEF has signed a long-term agreement with Moderna for the supply of COVID-19 vaccine on behalf of the COVAX Facility.
Through the supply agreement, UNICEF, along with procurement partners including the PanAmerican Health Organization (PAHO), will have access to up to 34 million doses of the vaccine for around 92 countries and territories in 2021. This is the fifth supply agreement UNICEF has signed for COVID-19 vaccines, following previously announced agreements with the Serum Institute of India, Pfizer, AstraZeneca and Human Vaccine.
Moderna’s COVID-19 vaccine received a WHO Emergency Use Listing (EUL) on 30 April. On3 May, the COVAX Facility announced that it had signed an Advance Purchase Agreement to secure access to 34 million doses of COVID-19 vaccines from Moderna in the fourth quarter of 2021 and up to 466 million doses in 2022.
Deliveries of the vaccine are scheduled to begin in the fourth quarter of 2021, with allocations to COVAX participants determined by the COVAX Allocation Framework that focuses on equity in access, considering amongst other parameters country readiness and supply through COVAX to date, and operating and supply considerations.
The goal of the COVAX Facility is to help address the acute phase of the global pandemic by the end of 2021 by providing rapid, fair and equitable access to safe and effective vaccines to all participating countries and territories regardless of income level.
The COVAX Facility, co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, together with UNICEF, aims to provide access to approved COVID-19 vaccines, enabling the protection of frontline health care and social workers, as well as other high-risk and vulnerable groups.
Additional resources for media
UNICEF works in some of the world’s toughest places, to reach the world’s most disadvantaged children. Across 190 countries and territories, we work for every child, everywhere, to build a better world for everyone. For more information about UNICEF and its work for children, visit www.unicef.org. Find out more about UNICEF’s role in COVAX here, UNICEF’s COVID-19 work here, or work on immunization here. Follow UNICEF on Twitter and Facebook.
About the COVAX Facility
COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO.
Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world. More: www.who.int/initiatives/act-accelerator/covaxUNICEF, in collaboration with the PAHO Revolving Fund, is leading efforts to procure and supply doses of COVID-19 vaccines on behalf of the COVAX Facility.